Rasonque Wins EU Approval for Metastatic Pancreatic Cancer — But When Can Patients Get It?

European Union flag outside an institutional building, illustrating the European Commission's approval of Rasonque for metastatic pancreatic cancer

MEDISEARCHER NEWS

European Union · Pancreatic cancer · 18 November 2026

In brief

  • The European Commission granted marketing authorisation to Rasonque (daraxonrasib) on 16 November 2026 for adults with previously treated metastatic pancreatic adenocarcinoma.
  • Rasonque is the first broad RAS-targeted medicine authorised in the EU for this form of metastatic pancreatic cancer.
  • The once-daily oral treatment is authorised after at least one previous systemic therapy, whether or not a tumour RAS mutation has been identified.
  • The approval follows a positive European Medicines Agency recommendation on 15 October and results from the Phase 3 RASolute 302 trial.
  • The authorisation applies throughout the European Union, but it does not mean Rasonque is already routinely available or reimbursed in every country.
  • Italy update, 18 November: The Italian Medicines Agency (AIFA) has begun a rolling review of daraxonrasib evidence to accelerate its national assessment and support equitable patient access. No Italian reimbursement decision or routine availability date has been announced.
  • Revolution Medicines is working on European patient access, with timing dependent on national pricing, health technology assessment and reimbursement processes.

The European Commission has approved Rasonque (daraxonrasib) for adults with previously treated metastatic pancreatic cancer, completing a major European regulatory milestone for a targeted treatment that demonstrated substantial survival benefits in clinical trials.

The decision, issued on 16 November 2026, grants EU marketing authorisation for Rasonque as a once-daily oral monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment.

However, regulatory approval is not the same as immediate patient availability. Pricing, reimbursement and healthcare-system arrangements will determine when eligible patients can routinely receive Rasonque in individual European countries.

What exactly has the European Commission approved?

According to the European Commission’s official Union Register of medicinal products, Rasonque has received centralised marketing authorisation under EU registration number EU/1/26/2079.

The approved indication is:

Rasonque as monotherapy for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.

The authorisation covers treatment with daraxonrasib alone, rather than in combination with chemotherapy or another anticancer medicine.

Revolution Medicines has confirmed that the indication includes eligible patients with or without an identified tumour RAS mutation. This is important because it means the authorised indication is not restricted to one particular RAS mutation.

The marketing authorisation holder is Revolution Medicines Netherlands B.V., based in Amsterdam.

The European Commission’s decision is recorded as C(2026) 8340, dated 16 November 2026.

Which European countries does the approval cover?

The centralised marketing authorisation applies across all 27 European Union member states, including Germany, France, Italy, Spain, Sweden, Poland, Ireland, Greece and Malta.

The authorisation also extends to the European Economic Area countries Iceland, Norway and Liechtenstein.

However, it does not constitute marketing authorisation in the United Kingdom or Switzerland, which have separate regulatory procedures.

For patients, the most important distinction is that EU-wide authorisation establishes a common regulatory basis for marketing the medicine, but does not guarantee immediate access through every national healthcare system.

How effective was Rasonque in clinical trials?

The European approval is supported by the randomised Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic adenocarcinoma.

The trial demonstrated improvements in both overall survival and progression-free survival.

According to the European Medicines Agency’s assessment:

  • Median overall survival: 12.4 months with Rasonque compared with 6.7 months with standard chemotherapy.
  • Median progression-free survival: 7.2 months with Rasonque compared with 3.6 months with chemotherapy.

Revolution Medicines has also reported a later overall-survival analysis showing median survival of 13.2 months with Rasonque compared with 6.7 months with chemotherapy, corresponding to a reported 60% reduction in the hazard of death.

These figures come from different analysis cut-off dates and should not be treated as contradictory results or directly interchangeable estimates.

Median survival describes the time at which half the patients in a treatment group have experienced the relevant outcome. It does not predict how long an individual patient will live.

The trial results support Rasonque as a significant new treatment option, but the medicine is not a cure for pancreatic cancer.

Why is Rasonque considered an important new cancer treatment?

Rasonque is a targeted medicine designed to interfere with RAS signalling, a pathway that plays a central role in the development and progression of many pancreatic cancers.

RAS proteins regulate cellular growth and survival. In pancreatic adenocarcinoma, abnormal RAS activity is a major driver of tumour growth.

Daraxonrasib works by binding to a protein called cyclophilin A, forming a complex that interacts with active RAS proteins and blocks their signalling activity.

This differs from conventional cytotoxic chemotherapy, which generally acts on rapidly dividing cells rather than targeting the RAS signalling pathway.

The medicine’s broad RAS-targeting mechanism is particularly significant because the European indication does not require identification of a specific tumour RAS mutation.

Why was Rasonque approved so quickly in Europe?

Rasonque received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on 15 October 2026.

The medicine had been selected for an expedited phased review under the EMA’s Cancer Medicines Pathfinder project, reflecting its potential to address a major unmet medical need.

The phased approach allowed the regulator to begin assessing parts of the evidence before the complete marketing-authorisation application had been submitted.

The EMA reported that the review required fewer than 150 active assessment days, compared with up to 210 active days for a standard evaluation.

The European Commission granted authorisation approximately one month after the positive CHMP opinion.

MediSearcher previously covered the clinical evidence and regulatory recommendation in its report on Rasonque’s progress towards European approval for pancreatic cancer.

When will Rasonque actually become available in Europe?

There is not yet a single confirmed date for routine patient availability across the European Union.

Although Rasonque now has centralised marketing authorisation, practical access will depend on country-specific arrangements.

Revolution Medicines said on 16 November that it is working with healthcare systems and stakeholders across Europe to support timely access for eligible patients.

However, the company has not announced a single EU-wide commercial launch date or a comprehensive schedule of national reimbursement decisions.

Patients may therefore encounter different timelines depending on where they live and how their national healthcare system evaluates and funds newly authorised cancer medicines.

Italy has already announced that its medicines regulator is reviewing the available daraxonrasib evidence through a rolling assessment process. This is a significant national access development, although it does not establish when the medicine will become routinely available or reimbursed in Italy.

For further context, MediSearcher’s guide to prescription costs and reimbursement across the EU explains why regulatory approval does not automatically mean a medicine is publicly funded or immediately accessible.

What happens with pricing, reimbursement and health technology assessment?

European marketing authorisation establishes that a medicine meets the applicable regulatory requirements for quality, safety and efficacy for its authorised indication.

It does not establish a common price or a single EU-wide reimbursement policy.

Individual countries retain responsibility for decisions about whether, how and under what conditions medicines are funded through their healthcare systems.

These processes may involve:

  • Health technology assessment: Evaluating the medicine’s clinical benefits and its place in treatment relative to available alternatives.
  • Pricing negotiations: Determining the terms under which the medicine may be supplied within a national market.
  • Reimbursement decisions: Establishing whether public healthcare systems will cover the treatment and which patients qualify.
  • Hospital implementation: Ensuring oncology centres can prescribe, obtain and administer or dispense the medicine appropriately.

Rasonque also falls within the scope of the EU Health Technology Assessment Regulation, under which a joint clinical assessment can support national evaluations.

The joint clinical assessment is separate from the EMA’s marketing-authorisation review. National authorities remain responsible for their own pricing and reimbursement decisions.

As of 19 November 2026, Italy has confirmed that its national assessment is underway, but no Italian reimbursement decision or routine patient-access date has been announced. No comprehensive European commercial rollout timetable has been identified in the sources reviewed for this article.

Italy begins early assessment of Rasonque to accelerate patient access

On 18 November 2026, the Italian Medicines Agency (AIFA) announced that it had already begun evaluating daraxonrasib, the active substance in Rasonque, following the European Medicines Agency’s positive recommendation for previously treated metastatic pancreatic cancer.

In its official announcement, AIFA confirmed that it had initiated a progressive assessment of the available evidence using a rolling review approach.

This means the agency is assessing clinical and regulatory information progressively rather than waiting to begin all its evaluation work at a later stage.

AIFA said the objective is to optimise the assessment timetable and facilitate access to treatment as quickly as possible, while maintaining scientific rigour and equitable access for eligible patients.

The regulator specifically emphasised the importance of avoiding geographical inequalities, so that eligible patients are not disadvantaged simply because of where they live within Italy.

This is particularly relevant for metastatic pancreatic cancer, where treatment decisions may be time-sensitive and patients who have already received systemic therapy can have limited remaining options.

Does AIFA’s announcement mean Rasonque is available in Italy?

No. The announcement confirms that the national assessment process is underway, not that Rasonque has received an Italian reimbursement decision or become routinely available through the Italian National Health Service (SSN).

Although Rasonque now has European Commission marketing authorisation, Italian patient access still depends on the applicable national procedures, including decisions affecting pricing, reimbursement and healthcare delivery.

AIFA has not announced a confirmed date for completion of its assessment or the start of routine publicly funded treatment.

The rolling review is nevertheless an important development because it indicates that the Italian regulator has begun preparatory evaluation work intended to reduce avoidable delays.

For patients and clinicians, the next meaningful milestone will be a formal national decision establishing the conditions under which eligible patients can obtain the medicine.

Until then, individual treatment and access questions should be discussed with the treating oncology team rather than interpreted as an automatic entitlement to Rasonque under the Italian healthcare system.

Greece provided Rasonque to selected patients before EU approval

One notable European access development occurred before the European Commission granted marketing authorisation.

On 6 November 2026, Greek Health Minister Adonis Georgiadis confirmed that selected patients with metastatic pancreatic cancer had received Rasonque free of charge through exceptional medicine-access arrangements.

The arrangements involved Greek healthcare organisations including IFET, EOPYY and EOF and followed earlier approval of individual patient access requests.

MediSearcher reported the development in its article on Greece providing early access to Rasonque before EU approval.

The Greek experience demonstrates that individual patients may sometimes obtain medicines through exceptional access pathways before standard European authorisation.

However, the arrangement should not be confused with routine national reimbursement or general commercial availability. Greece’s early-access measures do not establish that all eligible patients can automatically receive Rasonque.

Now that EU authorisation has been granted, further national decisions will determine how access develops through ordinary healthcare channels.

What are the side effects of Rasonque?

Like other anticancer treatments, Rasonque can cause adverse reactions and requires specialist medical supervision.

The European Medicines Agency has identified several common side effects, including:

  • diarrhoea;
  • rash;
  • stomatitis, or inflammation of the lining of the mouth;
  • nausea; and
  • vomiting.

Other adverse reactions and important warnings are described in the authorised European product information.

Patients should discuss the potential benefits and risks with their treating oncology team, taking into account previous treatments, other medical conditions and their individual circumstances.

What does the EU approval mean for pancreatic cancer patients?

The European Commission’s approval represents a major regulatory milestone for patients with metastatic pancreatic cancer who have already received systemic treatment.

Rasonque introduces a broad RAS-targeted treatment option supported by Phase 3 evidence of improved survival compared with standard chemotherapy.

Nevertheless, the practical significance of the approval will depend on how quickly national healthcare systems can make the medicine accessible to eligible patients.

For patients in countries where reimbursement and supply arrangements are not yet established, the approval does not necessarily mean treatment can begin immediately.

Patients should speak with their treating oncologist about their available treatment options and any applicable national access procedures. They should not attempt to obtain prescription cancer medicines through unverified online suppliers.

MediSearcher will continue monitoring significant national reimbursement, launch and patient-access decisions as Rasonque moves from European regulatory approval towards routine clinical availability.


Reviewed by: Dr Mattias Hagman, PhD

Editorial review: This article was prepared using the European Commission’s official marketing-authorisation record, European Medicines Agency regulatory information, clinical-trial reporting and Revolution Medicines’ authorisation announcement. The 19 November update also incorporates AIFA’s 18 November statement confirming its rolling assessment of daraxonrasib. Particular attention was given to distinguishing EU regulatory approval and national assessment activity from reimbursement decisions and practical patient access.

Last reviewed: 19 November 2026

Sources and verification

MediSearcher consulted the following primary and authoritative sources:

This article is provided for general informational purposes only and is not medical advice. EU marketing authorisation does not guarantee immediate availability or public reimbursement in every country. Treatment eligibility, access arrangements and prescribing decisions should be discussed with an appropriately qualified oncology specialist.